Skip to main content
Premium Trial:

Request an Annual Quote

Diagnostic Products Corporation Gets License to Compugen Prostate Proteins

NEW YORK, Jan. 22-Compugen has granted a license to Diagnostic Products Corporation to develop new assays for prostate cancer, the two companies said today.

 

The license, which covers two previously unidentified prostate-specific proteins, gives DPC the exclusive right to develop and commercialize assays for screening, detection and monitoring of cancer.

 

Compugen will receive milestone payments and royalties in the deal.

 

Compugen announced that it had discovered these two proteins last February. Both are encoded by mRNA splice variants of the genes for prostate-specific antigen.

 

Financial details of this agreement were not disclosed.

 

Diagnostic Products Corporation, based in Los Angeles, produces immunodiagnostic tests and manufactures laboratory instruments for diagnostics.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.